UNSPSC 51281511: Ethambutol dihydrochloride

This classification denotes an antitubercular agent with the molecular formula C10H24N2O2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QE4VW5FO07, chemically known as 1-butanol, 2,2'(1,2-ethanediyldiimino)bis-, dihydrochloride, (-(r*,r*)), but more generally known as ethambutol dihydrochloride, which bears US NIH Compound Identifier 3279. European Medicines Agency schedules ethambutol dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07271MIG.

Most nations, for tariff purposes, schedule ethambutol dihydrochloride under HS 29221980. SMILES: CC[C@@H](CO)NCCN[C@@H](CC)CO.CL.CL.

UNSPSC 51281511 Ethambutol dihydrochloride is a Commodity code identifying a specific tuberculosis pharmaceutical product, but state and local opportunities recently tagged under this code do not reflect procurement of ethambutol itself. Instead, the recent activity shows state and local health agencies using this code to acquire other pharmaceuticals and medical supplies — including antibiotic tablets, naloxone, and drug deactivation systems — through piggyback contracts and competitive bidding processes tied to public health missions. The issuing bodies are state health departments and county health authorities pursuing pharmaceutical supply and emergency medical response inventory. Procurement vehicles include cooperative purchasing consortiums (such as MMCAP Infuse) and traditional IFB processes. The tagged opportunities reflect both completed awards and active solicitations, though the products actually being supplied diverge substantially from the code's nominal pharmaceutical classification.

Illinois Department of Public Health awarded a piggyback pharmaceutical contract through MMCAP Infuse to Chartwell Rx LLC on August 28, 2026 (Bid 26-482DPH-PREPD-B-53392) for Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg tablets with a total award value of $2,999,999.11 over the contract life including renewal periods; the initial term spans 12 months with two one-year renewal options. Seminole County, Florida issued an IFB (IFB60459723LAS) posted June 30, 2026 with a response deadline of July 26, 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually for quarterly delivery to the Seminole County Community Health Building. Geographic activity is concentrated in Illinois and Florida based on recent tagged opportunities. The code's mismatch with actual procurement activity — tagged to a specific tuberculosis drug yet driving purchases of broader-spectrum antibiotics, opioid antagonists, and ancillary medical supplies — suggests either inconsistent coding practices in state local procurement systems or a wider code scope in practice than the commodity name indicates.